Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen: biochemistry, analytical methods, and clinical application

D A Armbruster1

  • 1Analytical Sciences Branch, US Air Force Drug Testing Laboratory, Brooks Air Force Base, TX 78235.

Clinical Chemistry
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Some personal reflections on downsizing.

Clinical laboratory management review : official publication of the Clinical Laboratory Management Association·1998
Same author

On-site drug testing on the rise and growing strong.

MLO: medical laboratory observer·1997
Same author

Non-pretreatment digoxin assays and developments in immunoanalyzers.

Clinical laboratory science : journal of the American Society for Medical Technology·1997
Same author

The quintessence of quality in the clinical laboratory.

Clinical laboratory management review : official publication of the Clinical Laboratory Management Association·1995
Same author

Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening.

Clinical chemistry·1995
Same author

Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs.

Clinical chemistry·1994
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
Same journal

Editor's Note: Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer.

Clinical chemistry·2026
Same journal

In Reply to Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
See all related articles

Prostate-specific antigen (PSA) is a valuable tumor marker for prostate cancer, aiding in diagnosis and monitoring treatment effectiveness. While useful, its specificity for general screening remains debated due to potential misdiagnosis with benign conditions.

Area of Science:

  • Biochemistry
  • Oncology
  • Urology

Background:

  • Prostate-specific antigen (PSA) is a key biomarker exclusively produced by prostate tissue.
  • Prostate cancer is a significant health concern in the aging male population.
  • Prostatic acid phosphatase (PAP) was previously used but has been largely replaced by PSA.

Purpose of the Study:

  • To highlight the utility of PSA as a tumor marker for prostate cancer.
  • To discuss the role of PSA in monitoring treatment efficacy, especially after prostatectomy.
  • To explore the challenges and debates surrounding PSA's use in general screening and differentiating benign conditions.

Main Methods:

  • Review of PSA's properties and clinical applications.
  • Comparison of PSA with previous markers like PAP.

Related Experiment Videos

  • Analysis of PSA's role in post-treatment monitoring and screening scenarios.

    • Main Results:

    • PSA offers greater clinical sensitivity than PAP for prostate cancer detection.
    • Post-prostatectomy PSA levels are crucial for identifying residual disease or recurrence.
    • PSA screening's utility is debated due to specificity issues and lack of proven mortality reduction.

    Conclusions:

    • PSA is an indispensable tool for diagnosing and monitoring prostate cancer.
    • Serial PSA measurements and PSA density can help differentiate prostate cancer from benign prostatic hypertrophy.
    • Further research is needed to optimize PSA screening strategies and address its limitations.